Lpath Promotes Leigh Hsu, Ph.D., to Vice President of Corporate Development
SAN DIEGO, CA -- (Marketwire) -- 02/13/13 -- Lpath, Inc. (NASDAQ:
LPTN), the industry leader in bioactive lipid-targeted therapeutics,
has promoted Leigh Hsu, Ph.D., to the new position of vice president
of corporate development.
Dr. Hsu has more than 13 years of business-development experience in
the biotech industry. Prior to joining Lpath in 2008 as its senior
director of business development, he held positions of increasing
responsibility at ACADIA Pharmaceuticals and Collateral Therapeutics
(which became a subsidiary of Schering AG, now Bayer). Dr. Hsu played
a key role in Lpath's $517 million licensing deal with Pfizer for
iSONEP(TM), and has extensive deal experience with organizations like
Wyeth and GE Healthcare, as well as with several academic and
research organizations, including the University of California, the
University of Texas, Southwestern Medical Center and the Veterans
Medical Research Foundation.
"Leigh has played a key business-development role at Lpath," said the
company's president and chief executive officer, Scott Pancoast. "He
contributed strongly to our worldwide iSONEP partnership with Pfizer
and has identified, and is now pursuing, several strategic licensing
opportunities for Lpath. Leigh has become an instrumental member of
the Lpath executive team, and we look forward to continued success on
his part, not only with our business-development mission but with the
corporate-strategy function as well."
In addition to Dr. Hsu's business experience, he has published
numerous scientific papers in peer-reviewed journals, primarily in
the area of the molecular basis of neurodegenerative diseases. He
received his Ph.D. in Molecular Pathology from the University of
California, San Diego, and his M.B.A. from the University of
San Diego-based Lpath, Inc., a therapeutic antibody
company, is the category leader in lipid-targeted therapeutics, an
emerging field of medicine that targets bioactive signaling lipids
for treating a wide range of human disease. Lpath's ImmuneY2(TM)
drug-discovery engine has the unique ability to generate therapeutic
antibodies that bind to and inhibit bioactive lipids that contribute
to disease. The company is developing three drug candidates:
iSONEP(TM) is currently in a Phase 2 trial for wet AMD; ASONEP(TM)
will soon begin a Phase 2 trial in Renal Cell Carcinoma patients; and
Lpathomab is a preclinical drug candidate that holds promise in pain,
neurotrauma, and other diseases.
Scott R. Pancoast
President & CEO
Lpath Investor Relations
Liolios Group, Inc.
Ron Both: email@example.com
Geoffrey Plank: firstname.lastname@example.org
Press spacebar to pause and continue. Press esc to stop.